United Healthcare Workers Re-Elect All Statewide Officers
...y national SEIU officials often have rules that make it very difficult to unseat the national president's appointees. At SEIU Local 6434, run by Stern protege Tyrone Freeman, Stern approved election rules that required challengers to collect 4,800 signatures within three weeks. According to the Los Angeles ...Lilly and MacroGenics Announce Licensing and Collaboration Agreement
...cule. Teplizumab is currently being studied in the protege trial, a global pivotal Phase II/III clinical tria...diabetes. MacroGenics will continue to oversee the protege trial. Under the terms of the agreement, MacroGen...tions, thus promoting immune tolerance. About the protege Trial The...Lilly Delivers Strong Third-Quarter Results
...ell as other potential next-generation molecules for use in the treatment of autoimmune diseases. Teplizumab is currently being studied in the protege trial, a global pivotal Phase II/III clinical trial for individuals with recent-onset type 1 diabetes. -- The company submitted a supplemental n...MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Three Independent Clinical Trials Initiated with Teplizumab Manufactured at MacroGenics ROCKVILLE, Md., Aug. 2 /PRNewswire/ -- MacroGenics, Inc. announced today that its Protege trial is actively enrolling adults and children ages 8 to 35 with recent-onset type 1 dia...MacroGenics Appoints New Vice President of Business Development
...l as other potential next-generation anti-CD3 molecules for use in the treatment of autoimmune diseases. Teplizumab is currently being studied in the protege trial, a global pivotal Phase II/III clinical trial for individuals with recent-onset type 1 diabetes (for more information, please visit www.protege...MacroGenics Raises $25M in Series D-2 Financing
...ip with Eli Lilly and Company. Teplizumab is currently being studied in the protege trial, a global pivotal Phase II/III clinical trial for individuals with re...atment of autoimmune diseases. Teplizumab is currently being studied in the protege trial, a global pivotal Phase II/III clinical trial for individuals with re...MacroGenics Acquires Raven Biotechnologies
...l as other potential next- generation anti-CD3 molecules for use in the treatment of autoimmune diseases. Teplizumab is currently being studied in the protege trial, a global pivotal Phase II/III clinical trial for individuals with recent-onset type 1 diabetes. MacroGenics' proprietary DART (Dual Affinity Re...